Article

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificity

2024-04-23

Abstract excerpt

P-cadherin (pCAD) and LI-cadherin (CDH17) are cell surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer. This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC). In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antib...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 615c2f24-8fbc-50cb-83ff-3fdde98b8731
DOI: 10.1101/2024.04.19.590291

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificityDOI 10.1101/2024.04.19.590291Read

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read

CDH17 as a Cell Surface Immunotherapy Target in Colorectal Cancer: An In Silico AnalysisSemantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read

The Target Atlas for Antibody-Drug Conjugates across Solid CancersSemantic proximity Read

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerSemantic proximity Read

ITC-6102RO, A Novel B7-H3 Antibody-Drug Conjugate, Exhibits Potent Therapeutic Effects against B7-H3 Expressing Solid TumorsSemantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerSemantic proximity Read

Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder CancerSemantic proximity Read